NCT01237119View on ClinicalTrials.gov

Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

Liraglutide

1.8 mg once daily, subcutaneous injection

OTHER

Liraglutide-placebo

1.8 mg once-daily, subcutaneous injection

Trial Locations (1)

B152TT

NIHR BRU Centre for liver research, Queens Elizabeth University Hospital Birmingham, Birmingham

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

Novo Nordisk A/S

INDUSTRY

lead

University of Birmingham

OTHER